ArticleAdvanced intelligent systems (Weinheim an der Bergstrasse, Germany)2020
Addressing COVID-19 Drug Development with Artificial Intelligence.
Article in Advanced intelligent systems (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blockchain applications in health care for COVID-19 and beyond: a systematic review.The Lancet. Digital health · 2021Pooled it
- Precision-Controlled Bionic Lung Simulator for Dynamic Respiration Simulation.Bioengineering (Basel, Switzerland) · 2025Article
- N-of-1 medicine.Singapore medical journal · 2024Article
- Article
- Intelligent selection of healthcare supply chain mode - an applied research based on artificial intelligence.Frontiers in public health · 2023Article
- A Blockchain-Based Life-Cycle Environmental Management Framework for Hospitals in the COVID-19 Context.Engineering (Beijing, China) · 2023Article
- Review on the COVID-19 pandemic prevention and control system based on AI.Engineering applications of artificial intelligence · 2022Review
- The Role of Artificial Intelligence and Machine Learning Amid the COVID-19 Pandemic: What Lessons Are We Learning on 4IR and the Sustainable Development Goals.International journal of environmental research and public health · 2022Article
- Using artificial intelligence technology to fight COVID-19: a review.Artificial intelligence review · 2022Article
- Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental andSaudi journal of biological sciences · 2022Article
- Robotics and artificial intelligence in healthcare during COVID-19 pandemic: A systematic review.Robotics and autonomous systems · 2021Review
- Applications of Artificial Intelligence, Machine Learning, Big Data and the Internet of Things to the COVID-19 Pandemic: A Scientometric Review Using Text Mining.International journal of environmental research and public health · 2021Review
- Fighting viruses with materials science: Prospects for antivirus surfaces, drug delivery systems and artificial intelligence.Dental materials : official publication of the Academy of Dental Materials · 2021Review
- Applications of artificial intelligence in battling against covid-19: A literature review.Chaos, solitons, and fractals · 2021Review
- IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development.Bioengineering & translational medicine · 2021Article
- Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data.Frontiers in artificial intelligence · 2021Article
- Contribution of machine learning approaches in response to SARS-CoV-2 infection.Informatics in medicine unlocked · 2021Review
- Application of lung microphysiological systems to COVID-19 modeling and drug discovery: a review.Bio-design and manufacturing · 2021Review
- Potential of artificial intelligence to accelerate diagnosis and drug discovery for COVID-19.PeerJ · 2021Article
- Overview of current state of research on the application of artificial intelligence techniques for COVID-19.PeerJ. Computer science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that led to the COVID-19 (Coronavirus Disease 2019) pandemic, has resulted in substantial overburdening of healthcare systems as well as an economic crisis on a global scale. This has in turn resulted in widespread efforts to identify suitable therapies to address this aggressive pathogen. Therapeutic antibody and vaccine development are being actively explored, and a phase I clinical trial of mRNA-1273 which is developed in collaboration between the National Institute of Allergy and Infectious Diseases and Moderna, Inc. is currently underway. Timelines for the broad deployment of a vaccine and antibody therapies have been estimated to be 12-18 months or longer. These are promising approaches that may lead to sustained efficacy in treating COVID-19. However, its emergence has also led to a large number of clinical trials evaluating drug combinations composed of repurposed therapies. As study results of these combinations continue to be evaluated, there is a need to move beyond traditional drug screening and repurposing by harnessing artificial intelligence (AI) to optimize combination therapy design. This may lead to the rapid identification of regimens that mediate unexpected and markedly enhanced treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.